Key Takeaways
- Blood cancers — leukaemia, lymphoma and myeloma — account for approximately 8–10% of all new cancer diagnoses in India annually.
- Early symptoms (persistent fatigue, unexplained weight loss, recurrent infections, enlarged lymph nodes) are frequently dismissed as routine illness — delaying diagnosis by months.
- Leukaemia treatment costs in Pune range from ₹3–15 lakh for a standard induction chemotherapy course; lymphoma treatment similarly ranges widely by subtype and stage.
- Insurance pre-authorisation for haematological malignancies is available through Baner hospital’s patient assistance team.
- Dr Deepak Patil offers bone marrow aspiration and biopsy, flow cytometry interpretation, and haematological malignancy management at Baner hospital.
- Newer targeted therapies (tyrosine kinase inhibitors, monoclonal antibodies) have dramatically improved outcomes for specific leukaemia subtypes.
Introduction
Blood cancers — collectively encompassing leukaemia (cancer of the blood and bone marrow), lymphoma (cancer of the lymphatic system) and multiple myeloma (cancer of plasma cells) — are a heterogeneous group of malignancies with widely varying prognoses, treatment approaches and costs. Unlike solid organ cancers, blood cancers are often systemic at presentation and require specialist haematological expertise for accurate diagnosis and management.
India sees approximately 1 lakh new haematological cancer cases annually, with a rising incidence attributed in part to improved diagnosis and reporting. Dr Deepak Patil, Haematologist at Baner Multi-Speciality Hospital, provides diagnostic and therapeutic haematology services for the western Pune population — offering blood cancer diagnosis, bone marrow biopsy, chemotherapy initiation and referral coordination as part of Baner hospital’s multi-disciplinary oncology service.
Quick Facts
| Parameter | Data |
| Annual new haematological cancer cases, India | ~1 lakh (industry estimate, ICMR) |
| Most common blood cancers in adults (India) | Non-Hodgkin lymphoma, chronic myeloid leukaemia (CML), multiple myeloma |
| Most common blood cancer in children | Acute lymphoblastic leukaemia (ALL) — 75–80% of paediatric leukaemia |
| 5-year survival, ALL (children) | >85% with modern chemotherapy protocols |
| 5-year survival, CML (with TKI therapy) | >90% — near-normal life expectancy with targeted therapy |
| Cost range, Pune 2026 | ₹3–15 lakh for initial induction; ongoing maintenance varies by drug and duration |
1. Types of Blood Cancer: A Plain-Language Guide
| Blood Cancer Type | Origin | Common Features | Treatment Overview |
| Acute lymphoblastic leukaemia (ALL) | Lymphoid precursor cells in bone marrow | Common in children; rapid onset; anaemia, bleeding, infection | Intensive multi-drug chemotherapy; >85% cure rate in paediatrics |
| Acute myeloid leukaemia (AML) | Myeloid stem cells | Adults most affected; rapid progression; requires immediate treatment | Induction chemotherapy ± stem cell transplant |
| Chronic myeloid leukaemia (CML) | BCR-ABL fusion protein (Philadelphia chromosome) | Gradual onset; enlarged spleen; often incidental diagnosis on CBC | Oral TKI (imatinib, dasatinib) — excellent long-term control |
| Non-Hodgkin lymphoma (NHL) | Lymphocytes; heterogeneous subtypes | Lymph node enlargement; B symptoms (fever, night sweats, weight loss) | R-CHOP or subtype-specific regimen; stage-dependent |
| Hodgkin lymphoma | Reed-Sternberg cells; young adults | Mediastinal mass; B symptoms; highly curable with chemo-radiation | ABVD regimen; 80–90% cure rate at early stages |
| Multiple myeloma | Plasma cells in bone marrow | Bone pain, anaemia, renal impairment, hypercalcaemia | Bortezomib-based therapy ± stem cell transplant |
2. Warning Signs and When to See a Haematologist
Many patients with blood cancer present late because early symptoms — fatigue, pallor, recurrent mild infections — are non-specific and easily attributed to overwork, nutritional deficiency or minor illness. Dr Patil emphasises the importance of a full blood count (CBC with differential) as the first-line investigation for any patient with persistent unexplained systemic symptoms.
- Persistent fatigue and pallor disproportionate to the degree of dietary deficiency.
- Unexplained weight loss of more than 10% body weight over 6 months without dieting.
- Recurrent infections that are unusually severe, prolonged or caused by organisms not typically pathogenic.
- Enlarged lymph nodes in the neck, armpits or groin that are painless and persist beyond 4–6 weeks.
- Night sweats and unexplained fever — the “B symptoms” of lymphoma.
- Easy bruising and prolonged bleeding from minor cuts — indicative of thrombocytopenia.
- Bone pain — particularly back pain in an older adult — that does not respond to analgesics (consider myeloma).
- An incidental finding of a high or low white cell count on a routine blood test — requires haematological evaluation.
3. Diagnosis: From Blood Test to Bone Marrow Biopsy
Blood cancer diagnosis requires a sequential workup that begins with the CBC and peripheral blood smear and culminates in bone marrow assessment and molecular characterisation. Dr Patil performs this entire pathway at Baner hospital, with the exception of advanced molecular testing (FISH, cytogenetics, NGS panels) which is sent to a reference laboratory.
| Diagnostic Step | Procedure | Indicative Cost (Pune 2026) | Turnaround |
| Complete blood count + differential | Automated haematology analyser + peripheral smear review | ₹300 – ₹600 | Same day |
| LDH, uric acid, renal/liver panel | Biochemistry profile — assesses disease burden and organ function | ₹1,500 – ₹3,000 | Same day |
| Bone marrow aspiration | Needle aspiration from posterior iliac crest; local anaesthesia | ₹5,000 – ₹10,000 | Report: 2–3 days |
| Bone marrow trephine biopsy | Core biopsy for histological architecture assessment | ₹8,000 – ₹15,000 | Report: 3–5 days |
| Flow cytometry (immunophenotyping) | Cell surface marker analysis — essential for leukaemia subtyping | ₹10,000 – ₹20,000 | 2–3 days (reference lab) |
| Cytogenetics / FISH | Chromosomal analysis — prognostic and treatment stratification | ₹15,000 – ₹35,000 | 7–14 days |
| PET-CT scan (lymphoma staging) | Whole-body metabolic imaging for lymphoma staging | ₹18,000 – ₹30,000 | Same/next day |
4. Treatment Costs in Pune 2026
Treatment costs for haematological malignancies vary enormously by diagnosis, stage, protocol and whether targeted therapy (typically more expensive than standard chemotherapy) is indicated. The following figures represent indicative ranges for initial treatment phases in Pune-based hospitals and should not be treated as fixed estimates without personalised assessment.
| Diagnosis | Treatment Phase | Indicative Cost Range (INR) |
| CML (all stages) | Oral TKI therapy (imatinib generic) | ₹3,000 – ₹8,000 per month (generic); significant price reduction vs branded |
| ALL (adult, induction) | Hospitalisation + chemotherapy (HYPER-CVAD or BFM protocol) | ₹4–8 lakh for induction; ₹1–2 lakh per consolidation cycle |
| AML (induction + consolidation) | DA-cytarabine protocol; HSCT referral if high-risk | ₹8–15 lakh for complete induction + consolidation |
| Hodgkin lymphoma (early stage) | ABVD chemotherapy x 4–6 cycles | ₹3–6 lakh total (generic drugs) |
| Non-Hodgkin lymphoma (R-CHOP) | 6–8 cycles with rituximab | ₹6–12 lakh (rituximab adds significant cost vs CHOP alone) |
| Multiple myeloma (VRd induction) | Bortezomib + lenalidomide + dexamethasone x 4 cycles | ₹8–18 lakh induction; ongoing maintenance separate |
Note: CGHS and Ayushman Bharat (PMJAY) schemes cover several haematological malignancies. Corporate group insurance plans typically cover cancer treatment. Baner hospital’s patient assistance team can help initiate pre-authorisation.
5. Supportive Care and Baner Hospital’s Role
Haematological malignancy treatment requires not only chemotherapy administration but comprehensive supportive care: packed red cell and platelet transfusions, antibiotic management of febrile neutropenia, anti-nausea medication, pain control and nutritional support. Baner hospital’s 24×7 laboratory, blood bank and HDU facilities allow most supportive care requirements to be managed on-site.
Dr Patil coordinates with Dr Bhalgat (Onco Surgery), the general physician team and paediatricians as needed for individual patient management plans. Referral to a dedicated bone marrow transplant (HSCT) centre is arranged through Baner hospital’s oncology network when transplant is indicated.
Frequently Asked Questions
1. Can blood cancer be cured?
Several blood cancers are curable — Hodgkin lymphoma has a cure rate exceeding 85%, paediatric ALL exceeds 85%, and early-stage diffuse large B-cell lymphoma (DLBCL) is curable in the majority of cases. CML is rarely cured but achieves deep remission with TKI therapy, allowing near-normal life expectancy. Outcomes depend critically on subtype, stage and treatment centre expertise.
2. Is a bone marrow biopsy painful?
The procedure is done under local anaesthesia and sedation if requested. The aspiration typically causes a brief, sharp pressure sensation rather than pain. Most patients find the experience less distressing than anticipated. Dr Patil explains the procedure in detail before proceeding and ensures patient comfort throughout.
3. My CBC shows high white blood cells. Does that mean I have leukaemia?
Not necessarily. Elevated white cell counts (leukocytosis) have many causes — infections, inflammatory conditions, steroid medications and reactive states. However, a persistent or very high white count, or an abnormal cell differential, requires haematological evaluation to exclude a haematological malignancy. A blood smear review and follow-up CBC are appropriate first steps.
4. Does chemotherapy have to be given in hospital for blood cancer?
Some blood cancer chemotherapy regimens are administered as day-care (patient arrives, receives infusion, goes home). Others require hospitalisation for monitoring, particularly during high-intensity induction phases. Dr Patil will specify the administration pathway at the time of treatment planning.
5. Are targeted therapies available in Pune?
Yes. Generic imatinib (for CML), generic rituximab (for B-cell lymphoma) and several other targeted agents are available at significantly lower cost than branded versions. Baner hospital’s oncology team prescribes generics where clinically equivalent, substantially reducing treatment costs.
Conclusion
Blood cancers encompass a wide spectrum of diagnoses — from highly curable conditions like Hodgkin lymphoma to more complex disorders requiring long-term management. The single most important factor in improving outcomes is early diagnosis: a full blood count remains the most accessible and cost-effective screening tool available.
Dr Deepak Patil and the haematology team at Baner Multi-Speciality Hospital offer a complete diagnostic and therapeutic pathway for blood disorders and haematological malignancies. To book a haematology consultation, visit banerhospital.com/haematology.
Medical Disclaimer
This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Always consult a qualified doctor or specialist before making any health-related decisions. The costs, statistics and clinical details mentioned are indicative and subject to change. For personalised advice, please book a consultation at Baner Multi-Speciality Hospital.
